ProPhase Labs (NASDAQ:PRPH – Get Free Report) is expected to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $3.77 million for the quarter.
ProPhase Labs Stock Performance
NASDAQ:PRPH opened at $0.40 on Thursday. ProPhase Labs has a twelve month low of $0.22 and a twelve month high of $7.48. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average of $0.44 and a 200-day moving average of $1.19. The firm has a market cap of $9.52 million, a price-to-earnings ratio of -0.32 and a beta of -0.53.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on shares of ProPhase Labs in a research report on Tuesday, February 25th. They set a “sell” rating for the company.
ProPhase Labs Company Profile
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Featured Articles
- Five stocks we like better than ProPhase Labs
- Insider Trades May Not Tell You What You Think
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Insider Buying Explained: What Investors Need to Know
- Alphabet’s Officially In A Bear Market—Time To Buy?
- How to Invest in the FAANG Stocks
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
